secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001493152-26-009321
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera reports positive Phase 2b results for Ameluz PDT in moderate-to-severe acne; plans FDA meeting in Q3 2026
--------------------------------------------------------------------------------

- Phase 2b study: 3-hour Ameluz incubation achieved 57.97% reduction in inflammatory lesions vs 36.51% for vehicle.
- 25% of Ameluz patients met mIGA co-primary endpoint (clear/almost clear) vs 21.4% with vehicle.
- Safety profile consistent with prior PDT; most treatment-related AEs were mild-to-moderate burning and pruritus.
- 85.7% of 3-hour Ameluz patients would choose PDT again; 71.4% rated esthetic outcome good/very good.
- Company to present data to FDA in Q3 2026 to discuss next steps for acne vulgaris indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315226009321/0001493152-26-009321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315226009321/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer